Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.Plos One8, e76781.(2013).
Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN.Blood.(2020).
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.Cancer.(2016).
Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the ASBMT.Biol Blood Marrow Transplant.(2015).
Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials.Front Med (Lausanne)2, 89.(2015).
Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant.Am J Hematol.(2016).
Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.Bone Marrow Transplant.(2018).
Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia.Biol Blood Marrow Transplant.(2016).
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.Cancer.(2016).
Revised-International Staging System (R-ISS) is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma (MM)..Biol Blood Marrow Transplant.(2018).
Staging Systems for Newly Diagnosed Myeloma Patients undergoing Autologous Hematopoietic Cell Transplant: The Revised International Staging System shows the most Differentiation between Groups.Biol Blood Marrow Transplant.(2018).
Umbilical cord blood: advances and opportunities.Cytotherapy17, 693-694.(2015).